Serum ferritin level and morbidity risk in transfusion-independent patients with β-thalassemia intermedia: The orient study

Haematologica

Volumn 99, Issue 11, 2014, Pages e218-e221

  Musallam, Khaled M ^a,b   Cappellini, Maria Domenica ^a   Daar, Shahina ^c   Karimi, Mehran ^d   El Beshlawy, Amal ^e   Graziadei, Giovanna ^a   Magestro, Matthew ^f   Wulff, Jerome ^g   Pietri, Guilhem ^g   Taher, Ali T ^b,h  

^a UNIVERSITY OF MILAN   (Italy)

^b AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^c SULTAN QABOOS UNIVERSITY   (Oman)

^d SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e CAIRO UNIVERSITY   (Egypt)

^f NOVARTIS PHARMA AG   (Switzerland)

^g Heron Evidence Development   (United Kingdom)

^h Chronic Care Center Hazmieh   (Lebanon)

Author keywords

Complications; Iron overload; Thalassemia

Indexed keywords

FERRITIN; HEMOGLOBIN;

ADOLESCENT; ADULT; AGED; BETA THALASSEMIA; BETA THALASSEMIA INTERMEDIA; CHILD; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; EXTRAMEDULLARY HEMATOPOIESIS; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; HYPOGONADISM; HYPOPARATHYROIDISM; HYPOTHYROIDISM; INFANT; IRON CHELATION; IRON OVERLOAD; LETTER; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORBIDITY; OSTEOPOROSIS; PRESCHOOL CHILD; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; SCHOOL CHILD; SPLENECTOMY; TRANSFUSION; YOUNG ADULT; BETA-THALASSEMIA; BLOOD; COMPLICATION; RISK;

BETA-THALASSEMIA; FERRITINS; HUMANS; IRON OVERLOAD; MORBIDITY; RISK;

EID: 84908459264     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.097220     Document Type: Letter

References (12)

1. Musallam KM, Rivella S, Vichinsky E, Rachmilewitz EA. Non-transfusiondependent thalassemias. Haematologica. 2013;98(6):833-44
2. Musallam KM, Cappellini MD, Taher AT. Iron overload in β-thalassemia intermedia: an emerging concern. Curr Opin Hematol. 2013;20(3):187-92.
3. Musallam KM, Cappellini MD, Wood JC, Taher AT. Iron overload in non-transfusion-dependent thalassemia: a clinical perspective. Blood Rev. 2012;26 Suppl 1:S16-9.
4. Ginzburg Y, Rivella S. β-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism. Blood. 2011;118(16):4321-30.
5. Taher AT, Viprakasit V, Musallam KM, Cappellini MD. Treating iron overload in patients with non-transfusion-dependent thalassemia. Am J Hematol. 2013;88(5):409-15.
6. Taher A, Vichinsky E, Musallam K, Cappellini M, Viprakasit V. Guidelines for the management of non transfusion dependent thalassaemia (NTDT). Nicosia, Cyprus: Thalassaemia International Federation, 2013.
7. Musallam KM, Cappellini MD, Wood JC, Motta I, Graziadei G, Tamim H, et al. Elevated liver iron concentration is a marker of increased morbidity in patients with β thalassemia intermedia. Haematologica. 2011;96(11):1605-12.
8. Musallam KM, Cappellini MD, Taher AT. Evaluation of the 5mg/g liver iron concentration threshold and its association with morbidity in patients with β-thalassemia intermedia. Blood Cells Mol Dis. 2013;51(1):35-8.
9. Taher AT, Porter J, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, et al. Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. Blood. 2012;120(5):970-7.
10. Taher AT, Porter JB, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, et al. Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study. Ann Hematol. 2013;92(11):1485-93.
11. Taher A, Porter J, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, et al. Estimation of liver iron concentration by serum ferritin measurement in non-transfusion-dependent thalassemia patients: analysis from the 1-year THALASSA study. Haematologica. 2012;96(S1):0927.
12. Taher A, Porter J, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, et al. Serum ferritin for predicting clinically relevant LIC thresholds to guide management of patients with nontransfusiondependent thalassemia treated with deferasirox: THALASSA study extension analysis [abstract]. Haematologica. 2013;98(S1):486.